Ilya Pharma

Ilya Pharma is a clinical-stage biotech pioneering a novel therapeutic modality using engineered, non-colonizing lactic acid bacteria to produce therapeutic proteins locally at disease sites. Its lead asset, ILP100 (emilimogene sigulactibac), expresses CXCL12 and is in development for topical wound healing and oral treatment of colitis, with positive Phase 1/2 data. The platform aims to unlock a wide range of previously undruggable proteins with a favorable cost and safety profile, targeting significant unmet needs in wound care, gastrointestinal diseases, and rare genetic conditions.

Engineered, non-colonizing lactic acid bacteria (Limosilactobacillus reuteri) used as local mini-bioreactors to produce and deliver therapeutic proteins (e.g., chemokines) directly at the site of disease in skin and mucosa. Classified as GTMP/gene therapy.

In wound healing, competitors include advanced biologics (e.g., growth factors), cell therapies, and other microbiome approaches. In colitis, it faces established anti-TNF and anti-integrin biologics. Ilya's key differentiation is its localized, sustained production of chemokines via a transient, non-colonizing bacterium—a unique mechanism of action.